Combination of Atorvastatin and Atorvastatin-pretreated Mesenchymal Stem Cells Improves the Cardiac Performance after Acute Myocardial Infarction by Targeting SDF-1/CXCR4 axis
机构：[1]Center for Cardiac Intensive Care, Beijing Anzhen Hospital临床科室心脏外科危重症中心首都医科大学附属安贞医院[2]State Key Laboratory for Cardiovascular Diseases, Fuwai Hospital
第一作者机构：[1]Center for Cardiac Intensive Care, Beijing Anzhen Hospital[2]State Key Laboratory for Cardiovascular Diseases, Fuwai Hospital
推荐引用方式(GB/T 7714)：
Tian Xiaqiu,Yang Yuejin.Combination of Atorvastatin and Atorvastatin-pretreated Mesenchymal Stem Cells Improves the Cardiac Performance after Acute Myocardial Infarction by Targeting SDF-1/CXCR4 axis[J].JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY.2018,72(16):C69-C69.doi:10.1016/j.jacc.2018.08.401.
APA：
Tian, Xiaqiu&Yang, Yuejin.(2018).Combination of Atorvastatin and Atorvastatin-pretreated Mesenchymal Stem Cells Improves the Cardiac Performance after Acute Myocardial Infarction by Targeting SDF-1/CXCR4 axis.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,72,(16)
MLA：
Tian, Xiaqiu,et al."Combination of Atorvastatin and Atorvastatin-pretreated Mesenchymal Stem Cells Improves the Cardiac Performance after Acute Myocardial Infarction by Targeting SDF-1/CXCR4 axis".JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 72..16(2018):C69-C69
医学